Advertisement


Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD, on PI3K and PD-L1 Inhibition Data

2014 San Antonio Breast Cancer Symposium

Advertisement

Lee S. Schwartzberg, MD, FACP of The West Clinic and Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute discuss the FERGI trial and data from phase I and phase II studies.



Related Videos

Breast Cancer

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.

Breast Cancer

Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive axillary nodes who convert to ypN0 after neoadjuvant chemotherapy? NSABP B-51/RTOG 1304 a phase III trial.”

Breast Cancer

Lisa A. Carey, MD, on Pembrolizumab in Advanced Triple-Negative Breast Cancer

Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09, "A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

Breast Cancer

Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

Jame Abraham, MD, FACP, of the Cleveland Clinic, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

Breast Cancer

Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH, on the Movement Toward Bilateral Surgical Procedures

Ismail Jatoi, MD, PhD, FACS, of the University of Texas Health Science Center and Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute discuss the increasing movement away from breast conservation toward bilateral surgical procedures.

Advertisement

Advertisement



Advertisement